Categories AlphaGraphs, Earnings, Health Care
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase in revenues.
Total revenues moved up 7% year-over-year to $3.16 billion in the three months ended March 2023. Excluding Ronapreve, revenues came in at $2.94 billion.
Meanwhile, the biotechnology firm’s first-quarter adjusted earnings dropped to $10.09 per share from $11.49 per share in the same period of 2022. Unadjusted profit was $818 million or $7.17 per share, compared to $974 million or $8.61 per share last year.
“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer.
Prior Performance
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
